Takeda says zasocitinib tops Bristol Myers’ deucravacitinib in Phase 3 psoriasis trial
TAK•Takeda said Phase 3 results for its investigational oral drug zasocitinib showed stronger skin-clearance outcomes and earlier responses than Bristol Myers Squibb’s deucravacitinib in plaque psoriasis. Zasocitinib is under FDA and EMA review for moderate-to-severe plaque psoriasis.
1. Phase 3 results
Takeda disclosed new Phase 3 data for zasocitinib at the EADV Congress 2026, showing stronger skin-clearance outcomes and earlier responses than Bristol Myers Squibb’s deucravacitinib. Separate pivotal trial updates indicated responses held over longer follow-up, with faster patient-reported improvements in itch and quality of life; safety remained consistent, with no new signals flagged.
